DEVICE Act of 2023

To amend the Federal Food, Drug, and Cosmetic Act to enhance medical device communications and ensure device cleanliness. 1. Short title This Act may be cited as the Disclosure; and Encouragement of Verification, Innovation, Cleaning, and Efficiency Act of 2023 DEVICE Act of 2023 2. Reporting requirement for design and reprocessing instruction changes (a) Adulteration Section 501 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 (k) If it is a device with respect to which the manufacturer is in violation of the reporting requirement under section 510(r) (relating to design and reprocessing changes). . (b) Requirement Section 510 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360 (r) Reporting requirement for device design changes Before making a change to the design of a device, or the reprocessing instructions of a device, that is marketed in interstate commerce, the manufacturer of the device shall give written notice of the change to the Secretary. . 3. Reporting requirement for certain communications to foreign health care providers (a) Adulteration Section 501 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 (l) If it is a device with respect to which the manufacturer is in violation of the reporting requirement under section 510(s) (relating to communications to foreign health care providers). . (b) Requirement Section 510 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360 (s) Reporting requirement for certain communications to foreign health care providers (1) Requirement The manufacturer of a device that is marketed in interstate commerce shall give written notice to the Secretary of any communication described in paragraph (2) not more than 5 calendar days after making such communication. (2) Communication described A communication is described in this paragraph if the communication— (A) is made by the manufacturer of the device or an affiliate of the manufacturer; (B) relates to a change to the design of the device, a change to the recommended reprocessing protocols, if any, for the device, or a safety concern about the device; and (C) is widely disseminated (including on a voluntary basis) to health care providers in a foreign country. (3) Affiliate In this subsection, the term affiliate (A) one business entity controls, or has the power to control, the other business entity; or (B) a third party controls, or has the power to control, both of the business entities. . 4. Rapid assessment tests intended to ensure proper reprocessing (a) Inclusion in device definition Section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 (1) in paragraph (h)(1)— (A) in clause (B), by striking or (B) in clause (C), by striking and or (C) by inserting after clause (C) the following: (D) a rapid assessment test intended to ensure the proper reprocessing of a reusable device (as defined in paragraph (ss)), and ; and (2) by adding at the end the following: (ss) The term reusable device (1) is intended to be used more than one time; and (2) must be sanitized (whether through cleaning, disinfection, or sterilization) to ensure that the device is safe and effective for such intended use. . (b) Instructions for use and validation data Section 510 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360 (t) Instructions for use and validation data (1) Initial list Not later than 1 year after the date of enactment of this subsection, the Secretary shall by regulation develop and publish a list of types of rapid assessment tests described in section 201(h)(1)(D) for which reports under subsection (k) must include— (A) instructions for use that have been validated in a manner specified by the Secretary; and (B) validation data, of the types specified by the Secretary. (2) Updates The Secretary shall by regulation periodically update the list required by paragraph (1). (3) Enforcement Beginning on the date of publication of the initial list under paragraph (1), the Secretary shall not accept any notification under subsection (k) for clearance of a type of rapid assessment test that is included on such list unless such notification includes instructions for use and validation data in accordance with paragraph (1). .

Summary: Disclosure; and Encouragement of Verification, Innovation, Cleaning, and Efficiency Act of 2023 or the DEVICE Act of 2023 This bill addresses design changes and reprocessing of medical devices. (Reprocessing of medical devices is the process for cleaning and sterilizing or disinfecting devices for reuse.) Specifically, medical device manufacturers must notify the Food and Drug Administration (1) before making changes to the design or reprocessing instructions of a device, and (2) no more than five days after widely disseminating to health care providers in a foreign country communications regarding changes to the design or reprocessing instructions of a device or regarding a safety concern about a device. A device may not be sold if the manufacturer violates these notification requirements.